Recombinant Human Filamin A-interacting protein 1-like(FILIP1L),partial CSB-EP679703HUa0
Specifications
| 20ug / 100ug / 1mg price = 100ug |
Alternative Name(s):
(130 kDa GPBP-interacting protein)(90 kDa GPBP-interacting protein)(Protein down-regulated in ovarian cancer 1)(DOC-1)
Species: (Organism)
Homo sapiens (Human)
Gene Names:
FILIP1L
Tag info:
N-terminal 6xHis-tagged
Target Protein AA Sequence:
MVVDEQQRLTAQLTLQRQKIQELTTNAKETHTKLALAEARVQEEEQKATRLEKELQTQTTKFHQDQDTIMAKLTNEDSQNRQLQQKLAALSRQIDELEETNRSLRKAEEELQDIKEKISKGEYGNAGIMAEVEELRKRVLDMEGKDEELIKMEEQCRDLNKRLERETLQSKDFKLEVEKLSKRIMALEKLEDAFNKSKQE
Expression Region:
1-200aa
Subcellular Location:
Tissue Specificity:
Protein Length:
Partial of Isoform 3
Pathway:
Mol. Weight:
27.6 kDa
Purity:
Greater than 85% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Cancer
Function:
Involvement in disease:
Relevance:
Acts as a regulator of the antiangiogenic activity on endothelial cells. When overexpressed in endothelial cells, leads to inhibition of cell proliferation and migration and an increase in apoptosis. Inhibits melanoma growth When expressed in tumor-associated vasculature.
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
Reference:
"Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy." Kwon M., Hanna E., Lorang D., He M., Quick J.S., Adem A., Stevenson C., Chung J.-Y., Hewitt S.M., Zudaire E., Esposito D., Cuttitta F., Libutti S.K. Cancer Res. 68:7332-7341(2008)
